Agastya Biopharm India Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
- Paid Up Capital ₹ 4.25 M
- Company Age 19 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Ebitda
- Net Worth
- Total Assets 0.75%
About Agastya Biopharm India
Agastya Biopharm India Limited (ABIL) is a Public Limited Indian Non-Government Company incorporated in India on 30 May 2005 and has a history of 19 years and eight months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 4.25 M, as per Ministry of Corporate Affairs (MCA) records.
Oduvangad Gopalakrishnan, Sidharthan Asan, Karthikeyan Gopalan, and Two other members serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24231KA2005PLC036421
-
Company No.
036421
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
30 May 2005
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Agastya Biopharm India?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Oduvangad Gopalakrishnan
|
Director | 23-Oct-2007 | Current |
|
Sidharthan Asan
|
Whole-Time Director | 15-Feb-2012 | Current |
|
Karthikeyan Gopalan
|
Director | 31-Dec-2009 | Current |
|
Madhu Ganghadharan
|
Director | 10-Jan-2011 | Current |
|
Radhakrishnan Sekharan
|
Director | 12-Aug-2011 | Current |
Financial Performance of Agastya Biopharm India.
Agastya Biopharm India Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Agastya Biopharm India?
In 2017, Agastya Biopharm India had a promoter holding of 25.61% and a public holding of 74.39%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Agastya Biopharm India?
Unlock and access historical data on people associated with Agastya Biopharm India, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Agastya Biopharm India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Agastya Biopharm India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
